Atypical dopamine-uptake inhibitors have low abuse potential and may serve as leads for the development of cocaine-abuse treatments. Among them, the benztropine (BZT) derivatives, JHW007 [N-(n-butyl)-3α-[bis-(4′-fluorophenyl)methoxy]-tropane hydrochloride], AHN2-005 [N-allyl-3α-[bis(4′-fluorophenyl)methoxy]- tropane oxalate], and AHN1-055 [3α-[bis(4′-fluorophenyl)methoxy]-tropane hydrochloride], dose-dependently decreased cocaine self-administration without effects on food-maintained responding. The present study examined selectivity by assessing effects of self-administration of other drugs. As with cocaine, each BZT analog dose-dependently decreased maximal self-administration of d-methamphetamine. In contrast, they were inactive against heroin and ketamine self-administration. These results support development of atypical dopamine uptake inhibitors as medication for stimulant abuse.
See article at J Pharmacol Exp Ther 2014, 348:174–191.
- Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics